Key result
Renal denervation had no significant effect on daytime systolic ambulatory blood pressure at 12 months (-4.2 mmHg; P=NS) in patients with resistant hypertension.
Why the study?
Does renal denervation reduce 24-hour ambulatory blood pressure and antihypertensive medication use in patients with resistant hypertension?
Observational (n=51)
Does renal denervation reduce 24-hour ambulatory blood pressure and antihypertensive medication use in patients with resistant hypertension?
p-value: p=NS
Renal denervation did not significantly reduce 24-hour ambulatory blood pressure at 12 months in patients with resistant hypertension when accounting for quantified medication changes.
Does not support renal denervation in resistant hypertension; leaves open its role pending randomized trials.
Background: Previous studies of renal denervation (RDN) have mainly focused on the effect on office blood pressure (BP) and number of antihypertensive drugs although these are known as sub-optimal endpoints. Aim: The aim of this study was to evaluate the effect of RDN by combining 24-hour ambulatory blood pressure (ABP) measurements and quantified antihypertensive medication at 12 months after RDN. Methods: Fifty-one patients (71% men, mean age 56 years) with resistant hypertension were treated with RDN. Office BP and ABP were measured at baseline and 6 and 12 months after RDN. Concomitantly the administration of antihypertensive drugs was assessed by their total defined daily dose (DDD). Results are presented as mean values ( ± SD)). Results: The change in daytime systolic ABP at 6 and 12 months was -8.6 (22.5) (P=0.01) and -4.2 (22.3) mmHg (P=NS). Quantified antihypertensive medication was assessed, and at 12 months after RDN there was no change in antihypertensive medication in 33% of patients using the DDD method versus 53% of patients using counts of number of antihypertensive drugs (NS). At 12 months after RDN a ≥5 mmHg reduction in MAP (24-hour ABP) was found in 36% of the patients in addition to an unchanged or reduced DDD, whereas this was seen in 42% of patients when number of antihypertensive drugs were used (NS). Conclusions: There was no effect of RDN on ABP after 12 months. We have presented a method that embraces both ABP and quantitative assessment of antihypertensive medication to evaluate RDN by combined ΔDDD/24-hour ΔMAP.
No takes yet. Share an insight, caveat, or question.
Lene Kjær Olsen (2015) conducted an observational in resistant hypertension (n=51). Renal denervation (RDN) was evaluated on Change in daytime systolic ambulatory blood pressure at 12 months (p=NS). Renal denervation had no significant effect on daytime systolic ambulatory blood pressure at 12 months (-4.2 mmHg; P=NS) in patients with resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: